Following this activity, participants should be able to: (1) Describe the role of a multidisciplinary team in determining treatment approach for patients with non-metastatic non-small cell lung cancer. (2) Recognize how molecular testing can inform treatment strategy for patients with non-metastatic non-small cell lung cancer. (3) Recognize the importance of molecular testing in patients with metastatic non-small cell lung cancer. (4) Review the types of systemic therapy that may be used to treat patients with metastatic non-small cell lung cancer.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Pricing
CME included with membership
| Free CME Activity | Free |
| Paid Activity (e.g. Breast/Lung Cancer Congress recordings) | $50 |
| Paid Activity (e.g. Hematologic Malignancies Congress recording) | $90 |
Collected from the provider’s public pages · source
Specialties served/covered
- Addiction Medicine
- Adolescent Medicine
- Anatomic & Clinical Pathology
- Colon & Rectal Surgery
- Communication & Shared Decision-Making
- Dermatopathology
- Evidence-Based Medicine & Research
- Gastroenterology
- Gastrointestinal Surgery
- General Surgery
- Geriatric Medicine
- Gynecologic Oncology
- Head & Neck Surgery
- Health Equity & Inclusion
- Hematology
- Hospice & Palliative Medicine
- Medical Genetics & Genomics
- Medical Leadership & Administration
- Medical Oncology
- Nephrology
- Neurology
- Obstetrics & Gynecology
- Pain Medicine
- Pediatric Hematology-Oncology
- Practice Management & Ethics
- Pulmonary Disease
- Radiation Oncology
- Surgical Oncology
- Thoracic Surgery
- Transplant Hepatology
- Urological Oncology
- Urology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pain & Palliative
- Pathology & Lab
- Primary care
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
- On-demand / recorded video
- Credit · Up to 1.5 credits
- MOC · Up to 1.5 points
- Paid · this provider typically $50
- Commercial Support
-
ReleasedJun 15, 2026
-
Last day to claim creditMar 2, 2027 5 months left
-
International Association for the Study of Lung Cancer Empowering Oncology Teams in HER2 Testing: Applying the New NCCN Standards to Transform NSCLC Care
-
PRIME Education, Inc. (PRIME®) Optimizing Biomarker Testing and First-Line Treatment Selection in Metastatic NSCLC
-
Annenberg Center for Health Sciences at Eisenhower Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer
-
National Comprehensive Cancer Network Archived NCCN Tumor Boards: Optimizing Clinical Decision-Making for Resectable Non-Small Cell Lung Cancer
-
National Comprehensive Cancer Network Multidisciplinary Coordination and Treatment Sequencing in Non-Small Cell Lung Cancer Care
-
National Comprehensive Cancer Network Managing EGFR-Positive, Non-Small Cell Lung Cancer Across the Treatment Spectrum: A Team-Based Approach
